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Background. Toxins are important Staphylococcus aureus virulence factors, but little is known about their
immunogenicity during infection. Here, additional insight is generated.
Methods. Serum samples from 206 S. aureus–infected patients and 201 hospital-admitted control subjects were
analyzed for immunoglobulin (Ig) G binding to 20 toxins, using flow-cytometry based technology. Antibody levels
were associated with polymerase chain reaction–defined presence of toxin genes in homologous S. aureus isolates.
Results. IgG levels directed to exfoliative toxin (ET) A, ETB, g hemolysin B (HlgB), leukocidin (Luk) D, LukE,
LukS, staphylococcal enterotoxin (SE) A, SEE, SEH, SEI, and SElM were higher in S. aureus–infected patients than
in control subjects ( ). Furthermore, in the S. aureus–infected patient group, IgG levels were higher if genesP ! .05
encoding ETA, ETB, SEA, SEC, SEH, SElQ, toxic shock syndrome toxin–1 (TSST-1), or Panton-Valentine leukocidin
(PVL) were present in the infectious isolate ( ). Levels of anti-SEA IgG increased during infections with sea-P ! .05
positive (median fluorescence intensity from 11,555 to 12,388; ) but not sea-negative strains. In addition,P ! .05
anti-LukS IgG levels increased during skin and soft-tissue infections with luk-PV–positive (median fluorescence
intensity from 15,231 to 15,911; ) but not luk-PV–negative strains. Bacteremia was associated with sea (oddsP ! .05
ratio, 3.4; 95% confidence interval, 1.2–10.0) and tst (odds ratio, 5.7; 95% confidence interval, 1.6–20.8). Skin
and soft-tissue infections and bone and joint infections were associated with luk-PV (odds ratio, 2.5; 95% confidence
interval, 1.2–5.2).
Conclusions. Many toxins are expressed in vivo and recognized by the immune system during staphylococcal
infections, suggesting their involvement in S. aureus pathogenesis.
Staphylococcus aureus produces numerous virulence
factors that contribute to its ability to cause infections
[1, 2]. These include a variety of toxins that are known
for their detrimental effects on cells of the immune
system [3]. In addition, their toxinogenic activity is
implicated in a broad range of S. aureus infections [4].
Staphylococcal toxins can be categorized in groups: py-
rogenic toxin superantigens (PTSAgs), exfoliative tox-
ins (ETs), leukocidins, and other toxins. The family of
PTSAgs includes staphylococcal enterotoxins (SEs),
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SE-like toxins [5], and toxic shock syndrome tox-
in-1 (TSST-1). Superantigens cross-link major histo-
compatibility complex class II molecules on antigen-
presenting cells with T cell receptors, which leads to
massive T cell proliferation and cytokine release [6].
This disproportionate proinflammatory activity is im-
plicated in the pathogenesis of food poisoning and toxic
shock syndrome [3, 7]. ETs are responsible for staph-
ylococcal scalded skin syndrome and bullous impetigo
[8]. Thus far, 4 ETs are known, and 3 of these (ETA,
ETB, and ETD) are linked to human infection [9].
Leukocidal toxins constitute a family of pore-forming
toxins that are composed of 2 distinct components. The
toxic effect depends on the synergistic action of both
class S and F proteins on human neutrophils or eryth-
rocytes. Members of the leukotoxin family are LukD,
LukE, LukM, g hemolysin (Hlg), and Panton-Valen-
tine leukocidin (PVL) [10, 11]. PVL is associated with
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Table 1. Bacterial Strains and Sequences of Primers Used for Staphylococcus aureus Toxin Production
Toxin
S. aureus
strains
Escherichia. coli
strains and
plasmids Primersa
Restriction
enzymes
SEA A87 0502 M15
pQE30
CTC AGG ATC CAA TGG TAG CGA GAA AAG CG
CTT TCT GCA GTT AAC TTG TAT ATA AAT ATA TAT CAA TAT GCA TG
BamHI/PstI
SEG A99 0372 M15
pQE30
CAA TGG ATC CCC CGA TCT TAA ATT AGA CGA AC
CGG ACT GCA GTC AGT GAG TAT TAA GAA ATA CTT CC
BamHI/PstI
SEI A900322 M15
pQE30
CTA TGG ATC CGG TGA TAT TGG TGT AGG TAA C
CGG ACT GCA GTT AGT TAC TAT CTA CAT ATG ATA TTT CGA C
BamHI/PstI
SElM A900322 M15
pQE30
GCA GGA TCC GAT GTC GGA GTT TTG AAT CTT AG
CGG ACT GCA GTC AAC TTT CGT CCT TAT AAG ATA TTT C
BamHI/PstI
TSST-1 N315 BL21 pLys
pIVEX 2.4d
TGG TAC TGG CGG CCGCTC TAC AAA CGA TAA TAT AAA GGA TTT G
CGGACTGCAGT TAATTAATTT CTGCTTCTAT AGTTTTTATT TCATC
NotI/PstI
HlgB ATCC 49775 BL21 pLys
pIVEX 2.4d
TGG TAC TGG CGG CCG CGA AGG TAA AAT AAC ACC AGT C
CGG GAT CCC TAT TTA TTG TTT TCA GTT TCT TTT GTA TC
NotI/BamHI
LukD A87 0555 BL21 pLys
pIVEX 2.4d
ACC CTT AAT TAA AGC TCA AAA TAT CAC ACC TAA AAG
ACG CGG ATC CTT ATA CTC CAG GAT TAG TTT CTT TAG
PacI/BamHI
LukE RN4220 BL21 pLys
pIVEX 2.4d
ACG CGG ATC CTT AAT TAT GTC CTT TCA CTT TAA TTT
ACC CTT AAT TAA AAA TAC TAA TAT TGA AAA TAT TGG TGA TGG TGC
BamHI/PacI
NOTE. HlgB, g hemolysin B; Luk, leukocidin; SE, staphylococcal enterotoxin; SEl, staphylococcal enterotoxin-like; TSST-1, toxic shock syndrome toxin-1.
a Restriction sites are underlined.
necrotizing pneumonia, bone and joint infections, epidemic
furunculosis, and abscesses in humans [12–15]. Toxins of the
epidermal cell differentiation inhibitor family inactivate
GTPases and thereby block important immune cell functions,
such as chemotaxis and phagocytosis [16].
Despite the fact that toxins are important staphylococcal
virulence factors and that the prevalence of S. aureus infection
is continuously increasing [17], little is known about the im-
munoglobulin (Ig) G response directed against PTSAgs, ETs,
and leukocidins during S. aureus infection in humans. By study-
ing the immune response, important information can be col-
lected concerning the antigenicity and in vivo expression of the
toxins. This may increase knowledge on pathogenesis of S.
aureus infection and might contribute to the development of
new measures against staphylococcal disease. We studied the
anti-toxin humoral immune response to 20 toxins in a large
number of S. aureus–infected patients and hospital-admitted
control subjects. Furthermore, we associated antibody levels
with the presence of toxin genes in infectious S. aureus isolates,
and we related toxin gene presence to different types of staph-
ylococcal infection.
MATERIALS AND METHODS
Collection of serum and S. aureus strains. S. aureus isolates
and 2 serum samples were collected from 206 S. aureus–infected
patients in the Mustapha Pacha hospital (Algiers, Algeria) dur-
ing 2006–2007. The first serum sample was obtained 5 days
(range, 0–20 days) after strain identification. The second sample
was collected 14 days (range, 7–34 days) thereafter. Serum sam-
ples were stored at 80C until use. Data on sex, age, hospital
ward, and type of infection were recorded. Isolates were con-
sidered to be community acquired if a sample obtained within
48 h after admission was culture positive for S. aureus. Isolates
obtained later were considered to be hospital acquired. Fur-
thermore, serum samples were collected for control patients
( ). Control patients were admitted in the same periodnp 201
but did not have an overt S. aureus infection. Patients with an
immunocompromised status (eg, human immunodeficiency vi-
rus–positive patients or patients receiving corticosteroids or
other immunosuppressive therapies) were excluded. Adult pa-
tients were defined as those aged 18 years. All patients pro-
vided written informed consent, and the local Medical Ethics
Committee of the Mustapha Pacha hospital approved the study.
Bacterial identification and toxin gene detection. S. aureus
was identified on the basis of colony and microscopic mor-
phology, coagulase testing with rabbit plasma (bioMe´rieux) and
the Staphyslide agglutination test (bioMe´rieux). The identifi-
cation was confirmed by multiplex polymerase chain reaction
(PCR) amplification of the accessory gene regulator (agr) [18]
and by determining the agr allelic group. The isolates were
PCR-screened for genes encoding methicillin resistance (mecA);
SE A, B, C, D, H, K, L, M, O, P, Q, and R (sea-d, seh, selk-m,
and selo-r); TSST-1 (tst); ETA, ETB, and ETD (eta, etb, and etd);
PVL (luk-PV); class F LukM leukocidin (lukM); HlgB (hlgb);
and epidermal cell differentiation inhibitor (edin), as described
elsewhere [18, 19].
Recombinant toxin production. The toxins SEC, SED, SEE,
SEH, SElJ, SElN, SElQ, SER, ETA, ETB, LukF, and LukS were
produced as described elsewhere [20–22]. The S. aureus strains
listed in Table 1 were used to produce the other toxins. Esch-
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Figure 1. A, Toxin-specific immunoglobulin (Ig) G levels in Staphylococcus aureus–infected patients versus control patients and adults versus children.
IgG levels are reflected by median fluorescence intensity (MFI) values. Black arrows indicate significant differences between the S. aureus–infected patient
and control patient group ( , by Mann Whitney U test). Results are shown for the first serum sample. B, Differences in toxin-specific IgG levelP ! .05
between the first and second serum sample and between different types of S. aureus infections in adults. The first bar of each pattern represents median
IgG level in the first serum sample; the second bar of the same pattern represents median IgG level in the second serum sample. ET, exfoliative toxin;
HlgB, g hemolysin B; Luk, leukocidin; SE, staphylococcal enterotoxin; SEl, staphylococcal enterotoxin-like; TSST-1, toxic shock syndrome toxin-1.
erichia coli M15 (Qiagen) and E. coli BL21 pLys (Invitrogen)
were used for plasmid amplification and genetic manipulations.
Primers were designed following the identification of suitable
hybridization sites in the toxin genes (Table 1). Chromosomal
DNA of S. aureus was extracted and used as a template for
PCR amplification as described previously [23]. The 5′ primers
were chosen within the coding sequence of each gene, omitting
the region predicted to encode the signal peptide, as determined
on the SignalP V3.0 World Wide Web Prediction Server (http:
//www.cbs.dtu.dk/services/SignalP/). The 3′ primers were cho-
sen to overlap the stop codon of the toxin genes (Table 1).
PCR products were codigested with appropriate restriction en-
zymes (Promega), purified with the High Pure PCR Product
Purification kit (Roche) and ligated using T4 DNA Ligase
(Roche) in either the pQE-30, pQE-70 (Qiagen), or pIVEX
2.4d expression vector (Roche) digested with the restriction
enzymes described in Table 1 [24]. The resulting pQE plasmids
were transformed into E. coli strain M15. For toxin expression
in pIVEX 2.4d, the vector was transformed into E. coli strain
DH5a (Invitrogen) before transformation into E. coli strain
BL21 pLys. Open reading frame integrity was verified by se-
quencing the junctions between the plasmid and the insert.
Protein purification. Transformed E. coli cells growing ex-
ponentially in Luria-Bertani (LB) medium supplemented with
ampicillin 100 mg/mL were inoculated into 1 liter of fresh LB
medium and incubated with continuous rotary shaking for 2–
3 h at 37C until OD600 0.5–0.7. Then, the expression was
induced by adding isopropyl-b-d-thiogalactopyranoside to a
final concentration of 1 mM for 5 h. The cultures were then
centrifuged at 4000 g for 20 min at 4C. The cell pellets were
stored overnight at 80C. The cell pellets were thawed for 15
min on ice and resuspended in lysis buffer (Qiagen). The lysates
were sonicated on ice after adding lysozyme. Then, the lysates
were centrifuged at 10,000 g for 30 min at 4C and the super-
natants were collected. The His-tagged proteins were purified
on Ni-nitrilotriacetic acid columns (Qiagen) and dialyzed
against phosphate-buffered saline. Protein concentrations were
determined according to the Bradford method, using bovine
serum albumin as the standard. The toxins were quality con-
trolled by sodium dodecyl sulphate–polyacrylamide-gel elec-
trophoresis and mass spectrometry (Ultraflex MALDI-ToF;
Bruker Daltonics).
Measurement of anti-toxin antibodies. Levels of IgG di-
rected against the toxins ETA, ETB, Hlgb, LukD, LukE, LukF,
LukS, SEA, SEC, SED, SEE, SEG, SEH, SEI, SElJ, SElM, SElN,
SElQ, SER, and TSST-1 were quantified simultaneously using
a bead-based flow cytometry technique (xMap; Luminex Cor-
poration). Methods were as described before [25–27]. Tests
were performed in independent duplicates, and the median
fluorescence intensity (MFI) values, reflecting semi-quantitative
antibody levels, were averaged. In each experiment, control
beads (no toxin coupled) were included to determine nonspe-
cific binding. In the event of nonspecific antibody binding, the
nonspecific MFI values were subtracted from the antigen-spe-
cific results. Human pooled serum was used as a standard [26].
Statistical analysis. Statistical analyses were performed
with SPSS software, version 15.0 (SPSS). Kruskal-Wallis and
Mann-Whitney U tests were used to compare differences in
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Table 2. Presence of Toxin Genes in Staphylococcus aureus Strains Isolated from Patients with Different Types
of S. aureus Infection
Toxin gene
No. (%) of gene-positive isolates
OR (95% CI)a P
SSTI
(n p 142)
Bacteremia
(n p 18)
Bone
infection
(n p 22)
Respiratory
infection
(n p 12)
Other
infection
(n p 12)
Total
(n p 206)
sea 20 (14) 6 (33) 1 (5) 2 (17) 1 (8) 30 (15) 3.4 (1.2–10.0) .024
seb 6 (4) 0 (0) 2 (9) 0 (0) 0 (0) 8 (4) … NS
sec 4 (3) 1 (6) 1 (5) 0 (0) 0 (0) 6 (3) … NS
seh 9 (6) 2 (11) 0 (0) 0 (0) 0 (0) 11 (5) … NS
selk 11 (8) 2 (11) 1 (5) 1 (8) 1 (8) 16 (8) … NS
sell 4 (3) 1 (6) 1 (5) 0 (0) 0 (0) 6 (3) … NS
selm 32 (23) 6 (33) 7 (32) 3 (25) 5 (42) 53 (26) … NS
selo 32 (23) 6 (33) 7 (32) 3 (25) 5 (42) 53 (26) … NS
selp 6 (4) 0 (0) 1 (5) 0 (0) 0 (0) 7 (3) … NS
selq 11 (8) 2 (11) 1 (5) 1 (8) 1 (8) 16 (8) … NS
tst 6 (4) 4 (22) 0 (0) 1 (8) 2 (17) 13 (6) 5.7 (1.6–20.8) .009
eta 2 (1) 0 (0) 0 (0) 1 (8) 0 (0) 3 (2) … NS
etb 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) … NS
etd 70 (49) 6 (33) 9 (41) 4 (33) 5 (42) 94 (46) … NS
luk-PV 71 (50) 5 (28) 11 (50) 4 (33) 3 (25) 94 (46) 2.5 (1.2–5.2) .015
hlgb 6 (4) 3 (17) 2 (9) 0 (0) 1 (8) 12 (6) … NS
edin 73 (51) 7 (39) 11 (50) 4 (33) 6 (50) 101 (49) … NS
NOTE. Boldfaced font indicates genes that are significantly more prevalent in strains isolated from a particular type of infection.
CI, confidence interval; edin, epidermal cell differentiation inhibitor; et, exfoliative toxin; hlgb, g hemolysin; luk-PV, Panton-Valentine
leukocidin; NS, not significant; OR; odds ratio; se, staphylococcal enterotoxin; sel, staphylococcal enterotoxin-like; SSTI, skin and soft-
tissue infection; tst, toxic shock syndrome toxin-1.
a ORs were calculated by use of binary logistic regression.
anti-toxin antibody levels between patients and control subjects.
The x2 test was applied for categorical variables and binary
logistic regression to calculate odds ratios (ORs). To compare
antibody levels in the first and second serum sample of each
patient, the Wilcoxon matched pairs signed rank test was used.
was considered statistically significant.P ! .05
RESULTS
Patient characteristics. The group of 206 S. aureus infected
patients consisted of 183 adults and 23 children. Their median
age was 40 years (range, 0–84 years). Male-to-female ratio was
1.5:1. Of the 206 patients, 142 (69%) had skin and soft tissue
infections (SSTIs; eg, furunculosis, infected skin lesions, or fol-
liculitis); 18 (9%) had bacteremia; 22 (11%) had bone or joint
infections (eg, arthritis or osteitis); 12 (6%) had respiratory
infection (eg, bronchitis); 3 (1%) had ocular infection (eg, con-
junctivitis or endophthalmitis); 2 (1%) had urinary tract in-
fection; 4 (2%) had ear, nose, or throat infection (eg, sinusitis);
and 3 (1%) had central nervous system infection. The group
of 201 control patients consisted of 143 adults and 58 children.
Median age was 45 years (range, 0–92 years) and the male-to-
female ratio was 1.1:1.
Validation and inter-assay variation of the toxin multiplex
assay. The MFI values obtained for human pooled serum with
the multiplex assay (serum incubated with the differently fluo-
rescence-colored antigen-coupled beads mixed in 1 well) were
between 90% and 111% (median 96%) of the MFI values ob-
tained with the individual assays (serum incubated with each
individual color of antigen-coupled beads in separate wells).
Therefore, the multiplex assay was considered reliable. Inter-
assay variation was calculated from MFI values obtained for
human pooled serum, which was included on each 96-wells
plate. MFI values were averaged per protein. The median co-
efficient of variation was 11% (range, 5%–18%), which is com-
parable to what was found in other studies [25, 28]
Differences in anti-toxin IgG levels between distinct types
of S. aureus infection. Antibody levels to 20 S. aureus toxins
were measured. The toxin-specific antibody levels showed ex-
tensive inter-individual variability. IgG levels directed to 11 of
20 toxins (ETA, ETB, HlgB, LukD, LukE, LukS, SEA, SEE, SEH,
SEI, and SElM) were significantly higher in adult S. aureus–
infected patients than in adult control patients in both the first
and second serum sample ( ) (Figure 1A). Adult patientsP ! .05
with respiratory infections, as opposed to other S. aureus in-
fections, had higher levels of IgG to SED (median MFI value,
2824 vs 1071; ), SElJ (5510 vs 2815; ), and SERP ! .01 P ! .01
(461 vs 133; ) (Figure 1B). In adult patients with SSTI,P ! .05
the level of anti-ETA IgG was elevated (5657 vs 2848; ).P ! .05
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Table 3. Difference in Presence of Toxin Genes between Methicillin-Resistant Staph-
ylococcus aureus (MRSA) and Methicillin-Susceptible S. aureus (MSSA) Isolates
Toxin gene
No. (%) of gene-positive isolates
MSSA
(n p 112)
MRSAa
(n p 94)
HA-MSSA
(n p 66)
CA-MSSA
(n p 46)
HA-MRSA
(n p 61)
CA-MRSA
(n p 33)
sea 28 (25) 2 (2)b 19 (29) 9 (20) 1 (2) 1 (3)
seb 8 (7) 0 (0)b 5 (8) 3 (7) 0 (0) 0 (0)
sec 6 (5) 0 (0)c 2 (3) 4 (9) 0 (0) 0 (0)
seh 11 (10) 0 (0)b 6 (9) 5 (11) 0 (0) 0 (0)
selk 10 (9) 6 (6) 6 (9) 4 (9) 5 (8) 1 (3)
sell 6 (5) 0 (0)c 2 (3) 4 (9) 0 (0) 0 (0)
selm 45 (40) 8 (9)b 23 (35) 22 (48) 7 (11) 1 (3)
selo 45 (40) 8 (9)b 23 (35) 22 (48) 7 (11) 1 (3)
selp 5 (5) 2 (2) 4 (6) 1 (2) 2 (3) 0 (0)
selq 10 (9) 6 (6) 6 (9) 4 (9) 5 (8) 1 (3)
tst 13 (12) 0 (0)b 9 (14) 4 (9) 0 (0) 0 (0)
eta 3 (3) 0 (0) 0 (0) 3 (7) 0 (0) 0 (0)
etb 1 (1) 0 (0) 1 (2) 0 (0) 0 (0) 0 (0)
etd 16 (14) 78 (83)b 9 (14) 7 (15) 48 (79) 30 (91)
luk-PV 17 (15) 77 (82)b 7 (11) 10 (22) 47 (77) 30 (91)
edin 21 (19) 80 (85)b 13 (20) 8 (17) 50 (82) 30 (91)
hlgb 12 (11) 0 (0)b 8 (12) 4 (9) 0 (0) 0 (0)
NOTE. CA, community acquired; HA, hospital acquired.
a P values !.05 (by the x2 test) were considered to be statistically significant.
b .P ! .01
c .P ! .05
In the course of SSTI, respiratory and bone and joint infections,
IgG levels showed no increase. In bacteremic patients, the level
of IgG directed to HlgB, LukD, LukE, LukF, LukS, and SEE
seemed to increase in the course of infection but this increase
was not statistically significant ( –.084) (Figure 1B).Pp .052
In S. aureus–infected children, IgG levels directed to 6 of 20
proteins (ETA, HlgB, LukD, LukE, LukF, and LukS) were sig-
nificantly higher ( ) (Figure 1A) than in children withoutP ! .05
S. aureus infections. Surprisingly, the level of anti-TSST-1 IgG
was higher in young control patients (median MFI 4804 vs
8195; ) than in S. aureus–infected patients. In the S.P ! .05
aureus patient group, IgG levels to 17 of 20 proteins were higher
in adults than children ( ). No difference was shown inP ! .05
anti-LukD, anti-LukF, and anti-SER IgG. In the control group,
IgG levels directed to all proteins were significantly higher in
adults than children ( ) (Figure 1A).P ! .001
Prevalence of genes encoding S. aureus toxins. The prev-
alence of genes encoding S. aureus toxins in the 206 infectious
isolates is shown in Table 2. Of 206 isolates, 182 (88%) harbored
1 toxin gene. The most prevalent genes were edin, luk-PV,
and etd, which were detected in 49%, 46%, and 46% of isolates,
respectively. Genes encoding SED, SER, and LukM were found
in none of the isolates. Bacteremia was associated with a higher
prevalence of the sea and tst gene. Isolates recovered from 6
(33%) of 18 bacteremic patients versus isolates from 24 (13%)
of 188 other patients were sea positive. Isolates from 4 (22%)
of 18 bacteremic patients versus isolates from 9 (5%) of 188
other patients were tst positive ( and , respectively)P ! .05 P ! .01
(Table 2). SSTI and bone and joint infections were associated
with a higher prevalence of luk-PV ( ). Isolates recoveredP ! .05
from 82 (50%) of 164 patients with SSTI or bone infection
versus 12 (29%) of 42 other patients were luk-PV positive
( ) (Table 2).P ! .05
Out of all infectious S. aureus isolates, 112 (54%) were meth-
icillin susceptible (MSSA), and 94 (46%) were methicillin re-
sistant (MRSA). The prevalence of sea, seb, sec, seh, sell, selm,
selo, tst, and hlgb was higher among MSSA stains; etd, luk-PV,
and edin were more prevalent among MRSA strains ( )P ! .05
(Table 3). Within the group of MSSA or MRSA infections, the
prevalence of toxin genes was not significantly different between
hospital-acquired and community-acquired infections (Table 3).
Association of anti-toxin IgG levels with presence of toxin
genes in infectious S. aureus isolates. Data on both gene
presence and anti-staphylococcal antibody levels were available
for 13 combinations (ETA, ETB, SEA, SEC, SED, SEH, SElM,
SElQ, SER, TSST-1, HlgB, LukS, and LukF). There were no
sed- and ser-positive isolates. Antibody levels were elevated if
the gene was present in 8 (eta, etb, sea, sec, seh, selq, tst, and
luk-PV) of 11 combinations ( (Figure 2). Furthermore,P ! .05
in patients with sea-positive S. aureus infection, the anti-SEA
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Figure 2. Box-and-whisker plots presenting the relation between toxin gene presences in isolates and the anti-toxin immunoglobulin (Ig) G levels in
serum from Staphylococcus aureus–infected patients. Results for eta and etb are not shown because of the small number of gene positive isolates
( and , respectively). The box represents the 25th, 50th, and 75th percentile, the whisker represents the lowest and highest obtained value.np 3 np 1
Luk, leukocidin; SE, staphylococcal enterotoxin; SEl, staphylococcal enterotoxin-like; TSST-1, toxic shock syndrome toxin-1.
IgG titers increased significantly in the course of infection (me-
dian MFI, from 11,555 to 12,388; ). In addition, in pa-P ! .05
tients with a SSTI caused by a luk-PV–positive strain, the level
of anti-LukS (not anti-LukF) IgG increased significantly (me-
dian MFI, from 15,231 to 15,911; ). No increase in IgGP ! .05
level was seen in sea- and luk-PV–negative S. aureus infections.
DISCUSSION
For the majority of toxins, anti-staphylococcal IgG levels were
higher in adults than children and IgG levels were higher in S.
aureus–infected patients than in hospital-admitted control sub-
jects (Figure 1A and 1B). This suggests that the anti-staphy-
lococcal humoral immune state of an individual develops over
the years and probably depends on the history of confrontations
with S. aureus. IgG levels in serum of patients were higher if
the toxin gene was present in their infectious isolates in 8 of
11 combinations (Figure 2). This indicates that eta, etb, sea,
sec, seh, selq, tst, and luk-PV are actively expressed and stimulate
the humoral immune system during S. aureus infections. For
PVL and SEA, there was additional support for expression in
vivo during S. aureus infections, as was found earlier by Croze
et al [29] for PVL. The level of anti-SEA IgG increased in a
time period of 2 weeks during infections caused by sea-positive
but not sea-negative strains. The level of anti-SEE IgG did not
increase, although earlier studies observed cross-reactivity with
anti-SEA antibodies [36]. Additionally, the level of anti-LukS
antibodies increased in the course of two weeks in patients
suffering from SSTI caused by luk-PV–positive but not luk-
PV–negative strains ( ). In contrast to LukS, IgG levelsP ! .05
to LukF were not higher if isolates were luk-PV positive, and
no increase anti-LukF IgG was detected in patients with a luk-
PV–positive SSTI. In mice, a dominant anti-LukS IgG2a and
2b response developed after immunizing mice subcutaneously
with both components. Furthermore, intranasally-vaccinated
mice generated anti-LukS IgA, but not anti-LukF IgA [30].
Therefore, it seems that LukS is the dominant antigenic protein
subunit, in mice as well as in humans.
For S. aureus infections that were caused by strains other
than strains positive for sea or luk-PV, the level of toxin-specific
IgG showed no increase in the course of infection. This suggests
that, in the case of SSTI, respiratory and bone and joint in-
fections, these infections did not elicit a strong systemic hu-
moral immune response. Alternatively, differences in antibody
levels between the 2 samples were nonsignificant because of the
high premorbid anti-toxin IgG levels. High preexisting IgG
levels might be the result of the high incidence of S. aureus
infections in this particular population. Subsequently, this
would suggest that these antibodies do not protect against these
types of staphylococcal infection. Preformed anti-toxin IgG
might also explain the high anti-SED and anti-SER IgG levels
that were found in patients with a respiratory infection, even
though the causative S. aureus isolates were sed and ser negative.
Bacteremia was associated with a high prevalence of sea and
tst, SSTI and bone and joint infections with a high prevalence
of luk-PV, in agreement with earlier studies [13, 31–33]. The
most prevalent genes in the 206 clinical S. aureus isolates of
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Algerian patients were edin (49%), luk-PV (46%), and etd
(46%) (Table 2). These genes were more prevalent among
MRSA than among MSSA strains ( ) (Table 3). Likely,P ! .05
this is due to the frequent occurrence of the luk-PV–, etd-, and
edin-positive MRSA-ST80 clone that is predominant in Algeria
[34, 35].
We measured IgG binding to toxins, but we do not have
data on neutralizing capacity and cross-reactivity of these an-
tibodies. In earlier studies, neutralizing capacity for anti-TSST-
1, SEA, SEB, SEC, and SEE antibodies was observed [6]. Cross-
reactivity was shown between anti-SEA and anti-SEE antibodies
and between anti-SEB and anti-SEC antibodies [36, 37]. For
other enterotoxins, antibody titers specific for heterologous tox-
ins were 10-fold lower than those directed against the toxin
used for immunization, which argues against a strong cross-
reactivity [6, 38]. Knowledge on cross-reactivity and function-
ality of the anti-toxin antibodies should be increased, though.
Furthermore, we do not know the S. aureus carrier state of the
patients. Because nasal carriers of S. aureus have an increased
risk of infection and nearly 80% of the infections are endog-
enous, their level of IgG might be influenced by coloniza-
tion and/or previous infections with their colonizing strain [39,
40]. Therefore, including nasal swab cultures in future stud-
ies is important.
In conclusion, during S. aureus infection, the toxins ETA,
ETB, SEA, SEC, SEH, SElQ, TSST-1, and Luk-PV are actively
expressed and recognized by the humoral immune system. S.
aureus bacteremia is associated with a high prevalence of sea
and tst whereas SSTI and bone and joint infections are asso-
ciated with presence of luk-PV. Significant increases in anti-
SEA IgG and anti-Luk-PV IgG levels are observed during all
types of infection and SSTI, respectively, suggesting their in-
volvement in staphylococcal pathogenesis.
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